Bu sayfada
NBIX Neurocrine Biosciences, Inc. - Common Stock
NASDAQ · Biotechnology · SEC EDGAR'da Görüntüle ↗ kapat Eki 5, 2026 10-K/10-Q Tem 31, 2026
$144,21
· 52 haftalık aralığın %'i
· düşüğün üstünde
· yükseğe
$123,0052 haftanın en düşüğü
$186,1252 haftanın en yükseği
Piyasa Değeri (MRQ)
$14.65B
P/E (TTM)
21.1
Hisse Başına Kâr (TTM)
$6.83
Gelir (TTM)
$3.37B
rozetleriniz
52 Haftlık Aralık
$123–$186
Analist Derecelendirmesi
BUY
Fiyat Hedefi
$208
P/E
21.1
ROE
22.1%
Net Kâr Marjı
20.9%
Rozet şeridiniz boş — bu sayfada herhangi bir metriği sabitleyin.
NBIX Hisse Senedi Özeti Fiyat, piyasa değeri, P/E, EPS, ROE, borç/öz sermaye, 52 haftalık aralık
Fiyat
$144.21
Piyasa Değeri (MRQ)
$14.65B
P/E (TTM)
21.1
Hisse Başına Kâr (TTM)
$6.83
Gelir (TTM)
$3.37B
ROE (TTM)
22.1%
52 Haftlık Aralık
$123–$186
NBIX Hisse Senedi Fiyat Grafiği Teknik göstergeler ile günlük OHLCV — kaydır, yakınlaştır ve görünümünüzü özelleştirin
aralık
çubuklar
Çubuk çözünürlüğü seçilen döneme uyum sağlar — bir çubuk için açılış/yüksek/düşük/kapanış değerlerini görmek için grafiğin üzerine gelin.
Neurocrine Biosciences, Inc. - Common Stock Hakkında Wikipedia'dan şirket genel bakışı
Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine (Ingrezza) was approved in the US to treat adults with tardive dyskinesia (TD).
The company is also developing treatments that are in various stages of clinical research for Parkinson's disease, Tourette syndrome, and congenital adrenal hyperplasia and with a partner for endometriosis and uterine fibroids.
History
Neurocrine was founded in San Diego, California, in 1992. The company's academic founders were Wylie Vale of the Salk Institute for Biological Studies, and Lawrence Steinman of Stanford University. The company was backed and organized by Larry Bock of Avalon Ventures among others.
In 1995, the company collaborated with Belgium-based Janssen Pharmaceutica N.V. to develop treatments for psychiatric disorders utilizing corticotropin releasing factor (CRF) antagonists, a class of compounds to treat psychiatric, neurological and gastrointestinal diseases including anxiety, depression and irritable bowel syndrome. The company underwent an IPO in May 1996, listing on the NASDAQ exchange under the symbol NBIX and raising $34.2 million.
In October 1996, Eli Lilly and Company agreed to pay Neurocrine $74 million over five years to develop drugs for obesity and Alzheimer's disease based on its research of CRF-binding protein-ligand inhibitors.
In July 2001, Neurocrine and GlaxoSmithKline entered into a worldwide research, development and commercialization agreement, including a collaborative research program for up to five years to identify and develop CRF-R antagonist compounds. The collaboration also included worldwide development and commercialization of NBI-34041 as well as potential backup candidates resulting from the research program. Neurocrine received upfront fees and early milestone payments totaling $25.5 million.
In December 2002, Neurocrine reached an agreement with Pfizer for the rights to its experimental insomnia drug, indiplon. The deal paid Neurocrine $100 million initially with a possible $300 million more if the drug met regulatory and sales goals. In May 2006, the FDA issued a non-approvable letter for a modified-release 15 mg formulation of indiplon and an approvable letter with stipulations for 5 mg and 10 mg immediate-release formulations. As a result, Pfizer terminated its agreement with Neurocrine. Following a resubmission of the 5 mg and 10 mg formulations in December 2007, Neurocrine's new drug application was deemed 'approvable' but the FDA requested additional studies. The company discontinued development of the drug in the United States. In 2007, Neurocrine partnered with Dainippon Sumitomo Pharma to develop and commercialize indiplon in Japan. The deal paid Neurocrine $20 million up front with the ability to receive milestone payments and royalties based on the commercialization of indiplon in Japan.
Kevin Gorman replaced Gary Lyons as CEO of the company in January 2008. Lyons was CEO and president of the company since its founding and maintained a role on the company's board of directors.
On June 16, 2010, Neurocrine agreed to a deal with AbbVie Inc. (previously Abbott Laboratories) worth up to $575 million with Neurocrine granting AbbVie the worldwide rights to develop and commercialize elagolix, an oral gonadotropin-releasing hormone (GnRH) antagonist to treat endometriosis and uterine fibroids. The deal paid Neurocrine $75 million up front.
In April 2017, the FDA approved valbenazine for the treatment of TD. At the time of approval, it was the first and only drug approved for adults with TD. Neurocrine is also studying valbenazine in clinical trials for the treatment of Tourette Syndrome. In October 2017, Neurocrine announced that it had been granted orphan drug designation status from the FDA for valbenazine for the treatment of pediatric patients with Tourette syndrome.
In February 2017, Neurocrine announced an exclusive licensing agreement for the development and commercialization of the Parkinson's disease drug, opicapone, in North America with the Portugal-based pharmaceutical company Bial. As part of the agreement, Neurocrine provided an upfront payment of $30 million and agreed to fund development activities for FDA approval in the United States. Bial is eligible to receive additional milestone payments of up to $115 million and a percentage of net sales.
In September 2017, AbbVie submitted a NDA to the FDA for elagolix for the management of endometriosis and associated pain. The submission was supported by two similar Phase 3 clinical studies involving 1,700 women. In October 2017, AbbVie and Neurocrine announced that the FDA granted priority review for the elagolix NDA. A final regulatory decision on the drug will come during the third quarter of 2018. The companies are also developing elagolix for the treatment of uterine fibroids which is in Phase III development.
In 2021,Nexera Pharmain Japan licensed out its investigational schizophrenia drug, NBI-1117568, to Neurocrine Biosciences for development.
In August 2024, Neurocrine announced the results of a Phase II clinical trial of NBI-1117568 . The drug demonstrated a 7.5-point improvement in the Positive and Negative Syndrome Scale (PANSS), which was lower than the 8.4-point improvement seen with KarXT (developed by Karuna Therapeutics) and the 12.7-point improvement seen with Emraclidine (developed by Cerevel Therapeutics), both of which were also in clinical trials at the time. Additionally, the study found no dose-dependent response to NBI-1117568. As a result, Neurocrine's stock price fell 19% the following day as investors were disappointed by the results.
Product pipeline
Elagolix – gonadotropin-releasing hormone receptor antagonist undergoing FDA review for the treatment of endometriosis and in clinical trials for uterine fibroids
Opicapone – A once daily catechol-O-methyl transferase inhibitor in trials for Parkinson's disease
NBI-74788 – Corticotropin-releasing factor (CRF) receptor antagonist
NBI-1117568 - A drug that stimulates muscarinic receptors and is used to treat schizophrenia.
Kaynak: Wikipedia (İngilizce), CC BY-SA 4.0 · Wikipedia'da Görüntüle ↗
sektörHealthcare
endüstriBiotechnology
çalışanlar2.500
ülkeUS
10 Yıllık Performans Gelir, net kar, marjlar ve EPS trendleri
Gelir$2.86B2016-12-31 → 2025-12-31
Hisse Başına Kâr$4.672016-12-31 → 2025-12-31
Serbest Nakit Akışı$749M2016-12-31 → 2025-12-31
Net kar marjı20.9%2016-12-31 → 2025-12-31
Değerleme ve Oranlar
Değerleme P/E, P/S, P/B, EV/EBITDA oranları — hisse senedi pahalı mı ucuz mu?
| Metrik | 5 Yıllık trend | NBIX | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| P/E (TTM) | 21.15Y ort. ≈58.9 | ≈58.9 | 19.4 | Aşırı değerli | |
| F/S (TTM) | 4.35Y ort. ≈6.5 | ≈6.5 | 7.3 | Düşük değerli | |
| F/D (MRQ) | 4.05Y ort. ≈5.6 | ≈5.6 | 14.5 | Düşük değerli | |
| Fiyat / Serbest Nakit Akışı (TTM) | 16.85Y ort. ≈29.9 | ≈29.9 | · | · | |
| Fiyat / Nakit Akışı (TTM) | 16.35Y ort. ≈28.0 | ≈28.0 | 13.6 | Aşırı değerli | |
| Fiyat / Maddi Defter Değeri (MRQ) | 10.05Y ort. ≈5.7 | ≈5.7 | · | · | |
| PEG Ratio (PEG Oranı) | ≈9.0 | · | · | · |
Akran ortalaması, metrik başına standartlaştırılmış bir temelde hesaplanır ve bu hisse senedi için gösterilen TTM/MRQ temelini her zaman eşleşmeyebilir.
Kârlılık Brüt, faaliyet ve net kâr marjları; ROE, ROA, ROIC
| Metrik | 5 Yıllık trend | NBIX | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Faaliyet Kâr Marjı (TTM) | 23.6%5Y ort. ≈17.0% | ≈17.0% | 15.8% | Aynı seviyede | |
| EBITDA Margin (FAVÖK Marjı) | 21.6%5Y ort. ≈17.0% | ≈17.0% | 15.8% | Aynı seviyede | |
| Vergi Öncesi Kar Marjı (TTM) | 27.9%5Y ort. ≈17.2% | ≈17.2% | 16.9% | Aynı seviyede | |
| Net Kâr Marjı (TTM) | 20.9%5Y ort. ≈12.5% | ≈12.5% | 15.1% | Aynı seviyede | |
| ROA (TTM) | 15.3%5Y ort. ≈8.4% | ≈8.4% | -0.46% | En üst düzey | |
| ROE (TTM) | 22.1%5Y ort. ≈11.4% | ≈11.4% | 17.4% | Aynı seviyede | |
| ROIC | 12.9%5Y ort. ≈10.8% | ≈10.8% | 14.5% | Zayıf |
Finansal Sağlık Borç, likidite, solventlik — bilanço gücü
| Metrik | 5 Yıllık trend | NBIX | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Cari Oran (MRQ) | 1.95Y ort. ≈3.2 | ≈3.2 | 3.3 | Düşük likidite | |
| Quick Ratio (Cari Oran) | 1.95Y ort. ≈1.8 | ≈1.8 | 2.5 | Düşük likidite |
Büyüme Gelir, EPS ve net gelir büyümesi: YOY, 3 Yıllık CAGR, 5 Yıllık CAGR
| Metrik | 5 Yıllık trend | NBIX | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Revenue YoY (Gelir Yıllık Bazda) | 21.4%5Y ort. ≈22.5% | ≈22.5% | · | · | |
| Revenue CAGR 3Y (Gelir 3 Yıllık Bileşik Büyüme Oranı) | 24.3%5Y ort. ≈24.6% | ≈24.6% | · | · | |
| Revenue CAGR 5Y (Gelir 5 Yıllık Bileşik Büyüme Oranı) | 22.3% | · | · | · | |
| EPS YoY (EPS YB) | 41.9%5Y ort. ≈25.0% | ≈25.0% | · | · | |
| Net Income YoY (Net Gelir Yıllık Bazda) | 40.2%5Y ort. ≈26.6% | ≈26.6% | · | · | |
| EPS CAGR 3Y (EPS Bileşik Yıllık Büyüme Oranı 3Y) | 44.1%5Y ort. ≈27.0% | ≈27.0% | · | · | |
| EPS CAGR 5Y (EPS Bileşik Yıllık Büyüme Oranı 5Y) | 2.3% | · | · | · | |
| Net Income CAGR 3Y (Net Gelir Bileşik Yıllık Büyüme Oranı 3Y) | 45.8%5Y ort. ≈29.0% | ≈29.0% | · | · | |
| Net Income CAGR 5Y (Net Gelir Bileşik Yıllık Büyüme Oranı 5Y) | 3.3% | · | · | · |
Sermaye Verimliliği Aktif devir hızı, stok devir hızı, alacak devir hızı
| Metrik | 5 Yıllık trend | NBIX | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Asset Turnover (Aktif Devir Hızı) | 0.75Y ort. ≈0.7 | ≈0.7 | 0.6 | Aynı seviyede | |
| Inventory Turnover (Stok Devir Hızı) | 0.85Y ort. ≈0.8 | ≈0.8 | 1.6 | Zayıf | |
| Receivables Turnover (Alacak Devir Hızı) | 4.95Y ort. ≈5.4 | ≈5.4 | 7.0 | Zayıf | |
| Revenue / Employee (Çalışan Başına Gelir) | ≈$1.1M | · | · | · |
değer · ≈ 5Y ort. · sektör ortalaması · ortalamaya göre değerlendirme
Kazanç Geçmişi EPS gerçekleşen vs tahmin, sürpriz %, kazanma oranı, bir sonraki kazanç tarihi
Ort. Sürpriz
11.3%
Sonraki Rapor
Eki 26, 2026
| Dönem | Rapor | EPS Gerçek | EPS Tahmin | Sürpriz |
|---|---|---|---|---|
| 30 Haziran 2026 | Tem 28, 2026 | $1.39 | $1.37 | 1.5% |
| 31 Mart 2026 | $1.91 | $1.20 | 59.5% | |
| 31 Aralık 2025 | $1.91 | $1.20 | 59.5% | |
| 30 Eylül 2025 | $2.04 | $1.62 | 26.1% | |
| 30 Haziran 2025 | $1.06 | $0.99 | 7.0% | |
| 31 Mart 2025 | $0.08 | $0.56 | -85.6% |
Tüm Temeller Tüm metrikler yıla göre — gelir tablosu, bilanço, nakit akışı
Gelir Tablosu
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.86B | $2.36B | $1.89B | $1.49B | $1.13B | $1.05B | $788M | $451M | $162M | $15M | $20M | $0 | |
| Cost of Revenue | $52M | $34M | $40M | $23M | $14M | $10M | · | $5M | $1M | $0 | $0 | · | |
| R&D Expense | · | · | · | · | · | · | · | $161M | $122M | $94M | $81M | $46M | |
| SG&A Expense | $1.16B | $1.01B | $888M | $753M | $583M | $433M | $354M | $249M | $170M | $68M | $32M | $18M | |
| Operating Expenses | $2.24B | $1.78B | $1.64B | $1.24B | $1.03B | $883M | $716M | $414M | $293M | $162M | $114M | $64M | |
| Operating Income | $619M | $570M | $251M | $249M | $102M | $163M | $72M | $37M | $-131M | $-147M | $-94M | $-64M | |
| Interest Expense | · | · | $5M | $7M | $26M | $33M | $32M | $30M | $20M | $0 | $0 | · | |
| Interest Income | · | · | · | · | · | · | · | · | · | $3M | $2M | $629.0K | |
| Other Non-op | $86M | $-84M | $81M | $-35M | $-1M | $-56M | $-26M | $-15M | $-11M | $6M | $20.0K | $18.0K | |
| Pretax Income | $705M | $486M | $332M | $214M | $101M | $107M | $46M | $22M | $-143M | $-141M | · | · | |
| Income Tax | $227M | $145M | $82M | $59M | $12M | $-301M | $10M | $700.0K | $0 | $0 | $0 | $0 | |
| Net Income | $479M | $341M | $250M | $154M | $90M | $407M | $37M | $21M | $-143M | $-141M | $-89M | $-61M | |
| EPS (Basic) | $4.81 | $3.40 | $2.56 | $1.61 | $0.95 | $4.38 | $0.40 | $0.23 | $-1.62 | $-1.63 | $-1.05 | $-0.81 | |
| EPS (Diluted) | $4.67 | $3.29 | $2.47 | $1.56 | $0.92 | $4.16 | $0.39 | $0.22 | $-1.62 | $-1.63 | $-1.05 | $-0.81 | |
| Shares (Basic) | 99,500,000 | 100,400,000 | 97,700,000 | 95,800,000 | 94,600,000 | 93,100,000 | 91,600,000 | 90,200,000 | 88,089,000 | 86,713,000 | 84,496,000 | 74,577,000 | |
| Shares (Diluted) | 102,500,000 | 103,700,000 | 101,000,000 | 98,900,000 | 97,900,000 | 97,800,000 | 95,700,000 | 95,400,000 | 88,089,000 | 86,713,000 | 84,496,000 | 74,577,000 | |
| EBITDA | $619M | $570M | $251M | $249M | $102M | $163M | $72M | $37M | $-131M | $-147M | · | $-64M |
Bilanço
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $713M | $233M | $251M | $263M | $341M | $187M | $112M | $142M | $255M | $83M | $74M | $31M | |
| Short-term Investments | · | · | · | · | $370M | $614M | $558M | $509M | $261M | $224M | $305M | $163M | |
| Receivables | $687M | $479M | $439M | $350M | $186M | $157M | $127M | $57M | $31M | $0 | · | · | |
| Inventory | $69M | $57M | $38M | $35M | $30M | $28M | $17M | $11M | $1M | $0 | · | · | |
| Prepaid Expense | $171M | $48M | · | · | · | · | · | · | · | · | · | · | |
| Other Current Assets | $116M | $64M | $98M | $79M | $46M | $30M | $17M | $19M | $7M | $3M | $5M | $4M | |
| Current Assets | $2.52B | $1.72B | $1.61B | $1.45B | $973M | $1.02B | $831M | $738M | $555M | $310M | $384M | $198M | |
| PP&E (Net) | $90M | $83M | $71M | $59M | $59M | $45M | $42M | $34M | $11M | $6M | $3M | $3M | |
| PP&E (Gross) | $208M | $189M | $154M | $125M | $110M | $86M | $76M | $62M | $38M | $32M | $30M | $31M | |
| Accum. Depreciation | $118M | $106M | $83M | $66M | $52M | $42M | $34M | $28M | $28M | $26M | $27M | $29M | |
| Goodwill | $6M | $6M | $6M | $5M | $0 | · | · | · | · | · | · | · | |
| Intangibles | $5M | $36M | $36M | $37M | $0 | · | · | · | · | · | · | · | |
| Other Non-current Assets | $49M | $52M | $50M | $25M | $4M | $6M | $0 | · | · | · | · | · | |
| Total Assets | $4.63B | $3.72B | $3.25B | $2.37B | $2.07B | $1.73B | $1.31B | $993M | $818M | $365M | $475M | $243M | |
| Accounts Payable | $674M | $462M | $449M | $348M | $226M | $169M | $141M | $86M | $6M | $5M | $3M | $246.0K | |
| Accrued Liabilities | · | · | · | · | · | · | · | · | · | $21M | $19M | $12M | |
| Current Liabilities | $743M | $508M | $655M | $538M | $246M | $186M | $565M | $88M | $54M | $30M | $26M | $16M | |
| Capital Leases | $415M | $455M | $258M | $94M | $105M | $94M | $87M | $0 | · | · | · | · | |
| Deferred Tax | $0 | · | · | · | · | · | · | · | · | · | · | · | |
| Other Non-current Liabilities | $220M | $166M | $106M | $30M | $12M | $10M | $17M | $36M | $0 | $113.0K | $221.0K | $260.0K | |
| Total Liabilities | $1.38B | $1.13B | $1.02B | $661M | $698M | $608M | $669M | $512M | $445M | $50M | $50M | $34M | |
| Common Stock | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $91.0K | $89.0K | $87.0K | $86.0K | $76.0K | |
| Paid-in Capital | · | · | · | · | · | · | · | · | · | · | · | $1.04B | |
| Retained Earnings | $448M | $29M | $-157M | $-407M | $-636M | $-725M | $-1.13B | $-1.18B | $-1.20B | $-1.06B | $-915M | $-826M | |
| AOCI | $13M | $6M | $7M | $-8M | $-2M | $2M | $1M | $-2M | $-2M | $-318.0K | $-977.0K | $-277.0K | |
| Stockholders' Equity | $3.25B | $2.59B | $2.23B | $1.71B | $1.37B | $1.13B | $637M | $481M | $372M | $315M | $424M | $209M | |
| Liabilities + Equity | $4.63B | $3.72B | $3.25B | $2.37B | $2.07B | $1.73B | $1.31B | $993M | $818M | $365M | $475M | $243M | |
| Shares Outstanding | 100,100,000 | 99,400,000 | 98,700,000 | 96,500,000 | 94,900,000 | 93,500,000 | 92,300,000 | 90,797,000 | 88,793,903 | 86,883,300 | 86,262,594 | 76,465,942 |
Nakit Akışı
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | · | · | · | · | · | $4M | $2M | $1M | $1M | $827.0K | |
| Stock-based Comp | $218M | $196M | $194M | $173M | $134M | $100M | $75M | $58M | $43M | $28M | $28M | $10M | |
| Deferred Tax | $164M | $-123M | $-61M | $22M | $6M | $-311M | $0 | $0 | · | · | · | · | |
| Amort. of Intangibles | $4M | $4M | $4M | $500.0K | $0 | $0 | · | · | · | · | · | · | |
| Operating Cash Flow | $783M | $595M | $390M | $339M | $256M | $228M | $147M | $101M | $-94M | $-106M | $-38M | $-47M | |
| CapEx | $34M | $38M | $28M | $16M | $23M | $11M | $15M | $25M | $7M | $4M | $2M | $2M | |
| Investing Cash Flow | $-264M | $-127M | $-467M | $-177M | $-130M | $4M | $-211M | $-243M | $-251M | $113M | · | · | |
| Stock Issued | $129M | $122M | $65M | $45M | $28M | $29M | $32M | $30M | $14M | $2M | $277M | $139M | |
| Stock Repurchased | $168M | $300M | $0 | $0 | · | · | · | · | · | · | · | · | |
| Net Stock Activity | $-38M | $-178M | $65M | $45M | $28M | $29M | $27M | $30M | $14M | $2M | · | $139M | |
| Financing Cash Flow | $-38M | $-487M | $65M | $-234M | $27M | $-158M | $32M | $30M | $517M | $2M | · | · | |
| Net Change in Cash | $480M | $-18M | $-12M | $-73M | $154M | $75M | $-32M | $-112M | $171M | $9M | $43M | $-14M | |
| Taxes Paid | $81M | · | · | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $749M | $557M | $362M | $323M | $233M | $218M | $137M | $77M | $-101M | $-110M | · | $-49M | |
| Levered FCF | · | · | $358M | $318M | $210M | $92M | $112M | $47M | · | · | · | · |
Kârlılık
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 21.6% | 24.2% | 13.3% | 16.7% | 9.0% | 15.6% | 9.2% | 8.2% | -81.3% | -982.5% | · | · | |
| Net Margin | 16.7% | 14.5% | 13.2% | 10.4% | 7.9% | 38.9% | 4.7% | 4.7% | -88.2% | -940.6% | · | · | |
| Pretax Margin | 24.7% | 20.6% | 17.6% | 14.4% | 8.9% | 10.2% | 5.9% | 4.8% | · | · | · | · | |
| EBITDA Margin | 21.6% | 24.2% | 13.3% | 16.7% | 9.0% | 15.6% | 9.2% | 8.2% | -81.3% | -982.5% | · | · | |
| ROA | 11.5% | 9.8% | 8.9% | 7.0% | 4.7% | 26.8% | 3.2% | 2.3% | -24.1% | -33.6% | · | -30.4% | |
| ROE | 16.1% | 12.9% | 11.8% | 9.5% | 6.6% | 42.2% | 6.1% | 4.5% | -41.5% | -38.2% | · | -36.8% | |
| ROIC | 12.9% | 15.5% | 8.5% | 10.5% | 6.6% | 55.2% | 9.0% | 7.4% | · | · | · | · |
Likidite ve Solventlik
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.4 | 3.4 | 2.5 | 2.7 | 4.0 | 5.4 | 1.5 | 8.4 | 10.2 | 10.2 | · | 12.7 | |
| Quick Ratio | 1.9 | 1.4 | 1.1 | 1.1 | 3.6 | 5.1 | 1.4 | 2.2 | 10.1 | 10.1 | · | 12.4 | |
| Interest Coverage | · | · | 54.5 | 35.1 | 4.0 | 5.0 | 2.3 | 1.2 | -6.7 | · | · | · |
Verimlilik
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.7 | 0.7 | 0.7 | 0.7 | 0.6 | 0.7 | 0.7 | 0.5 | 0.3 | 0.0 | · | 0.0 | |
| Inventory Turnover | 0.8 | 0.7 | 1.1 | 0.7 | · | · | · | 0.8 | · | · | · | · | |
| Receivables Turnover | 4.9 | 5.1 | 4.8 | 5.6 | 6.6 | 7.4 | 8.6 | 10.3 | 10.4 | · | · | · |
Hisse Başına
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $32.50 | $26.05 | $22.61 | $17.70 | $14.48 | $12.04 | $6.90 | $5.29 | $4.19 | $3.62 | · | $2.73 | |
| Revenue / Share | $27.91 | $22.71 | $18.68 | $15.05 | $11.58 | $10.69 | $8.23 | $4.73 | $1.83 | $0.17 | · | $0.00 | |
| Cash Flow / Share | $7.64 | $5.74 | $3.86 | $3.43 | $2.62 | $2.34 | $1.59 | $1.06 | $-1.07 | $-1.22 | · | $-0.63 | |
| Cash / Share | $7.12 | $2.34 | $2.54 | $2.72 | $3.59 | $2.00 | $1.22 | $1.56 | $2.87 | $0.96 | · | $0.41 | |
| EPS (TTM) | $4.67 | $3.29 | $2.47 | $1.56 | $0.92 | $4.16 | $0.39 | $0.22 | $-1.62 | $-1.63 | $-1.05 | $-0.81 |
Büyüme Oranları
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 21.4% | 24.8% | 26.8% | 31.3% | 8.4% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 24.3% | 27.6% | 21.7% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 22.3% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | 41.9% | 33.2% | 58.3% | 69.6% | -77.9% | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | 44.1% | 52.9% | -16.0% | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | 2.3% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | 40.2% | 36.7% | 61.6% | 72.4% | -78.0% | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | 45.8% | 56.2% | -15.0% | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | 3.3% | · | · | · | · | · | · | · | · | · | · | · |
Değerleme (TTM)
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $2.86B | $2.36B | $1.89B | $1.49B | $1.13B | $1.05B | $788M | $451M | $162M | $15M | $20M | $0 | |
| Net Income TTM | $479M | $341M | $250M | $154M | $90M | $407M | $37M | $21M | $-143M | $-141M | $-89M | $-61M | |
| Market Cap | $14.20B | $13.57B | $13.00B | $11.53B | $8.08B | $8.96B | $9.92B | $6.48B | $6.89B | $3.36B | · | $1.71B | |
| P/E | 30.4 | 41.5 | 53.3 | 76.6 | 92.6 | 23.0 | 275.6 | 324.6 | -47.9 | -23.7 | -53.9 | -27.6 | |
| P/S | 5.0 | 5.8 | 6.9 | 7.7 | 7.1 | 8.6 | 12.6 | 14.4 | 42.6 | 224.2 | · | · | |
| P/B | 4.4 | 5.2 | 5.8 | 6.7 | 5.9 | 8.0 | 15.6 | 13.5 | 18.5 | 10.7 | · | 8.2 | |
| P / Tangible Book | 4.4 | 5.3 | 5.9 | 6.9 | 5.9 | 8.0 | · | · | · | · | · | · | |
| P / Cash Flow | 18.1 | 22.8 | 33.4 | 34.0 | 31.5 | 39.2 | 65.2 | 64.0 | -73.0 | -31.7 | · | -36.2 | |
| P / FCF | 19.0 | 24.4 | 36.0 | 35.7 | 34.7 | 41.2 | 72.2 | 84.7 | -68.0 | -30.5 | · | -35.0 | |
| Earnings Yield | 3.3% | 2.4% | 1.9% | 1.3% | 1.1% | 4.3% | 0.36% | 0.31% | -2.1% | -4.2% | -1.9% | -3.6% |
Gelir Tablosu
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $959M | $814M | $806M | $795M | $688M | $573M | $628M | $622M | $590M | $515M | $515M | $499M | $453M | $420M | $412M | $388M | |
| Cost of Revenue | · | $14M | $18M | $14M | $11M | $9M | $9M | $8M | $9M | $8M | $8M | $11M | $12M | $8M | $8M | $6M | |
| SG&A Expense | $440M | $318M | $302M | $292M | $286M | $276M | $288M | $234M | $242M | $243M | $219M | $204M | $222M | $243M | $183M | $186M | |
| Operating Expenses | $808M | $621M | $595M | $556M | $542M | $549M | $486M | $438M | $445M | $416M | $365M | $358M | $379M | $535M | $309M | $300M | |
| Operating Income | $152M | $193M | $211M | $239M | $146M | $24M | $142M | $184M | $145M | $99M | $150M | $141M | $74M | $-114M | $103M | $88M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $1M | · | $1M | $1M | $1M | · | $1M | |
| Other Non-op | $11M | $53M | $28M | $53M | $14M | $-9M | $21M | $6M | $-47M | $-65M | $48M | $-26M | $48M | $11M | $14M | $10M | |
| Pretax Income | $162M | $247M | $239M | $292M | $160M | $15M | $163M | $190M | $99M | $34M | $198M | $116M | $122M | $-103M | $118M | $98M | |
| Income Tax | $18M | $49M | $86M | $82M | $52M | $7M | $60M | $60M | $34M | $-9M | $50M | $32M | $26M | $-27M | $29M | $29M | |
| Net Income | $144M | $198M | $154M | $210M | $108M | $8M | $103M | $130M | $65M | $43M | $148M | $83M | $96M | $-77M | $89M | $68M | |
| EPS (Basic) | $1.43 | $1.97 | $1.53 | $2.11 | $1.09 | $0.08 | $1.05 | $1.28 | $0.64 | $0.43 | $1.52 | $0.85 | $0.98 | $-0.79 | $0.92 | $0.72 | |
| EPS (Diluted) | $1.39 | $1.91 | $1.49 | $2.04 | $1.06 | $0.08 | $1.00 | $1.24 | $0.63 | $0.42 | $1.49 | $0.82 | $0.95 | $-0.79 | $0.91 | $0.69 | |
| Shares (Basic) | 101,000,000 | 100,500,000 | · | 99,400,000 | 99,000,000 | 99,700,000 | · | 101,100,000 | 100,800,000 | 99,800,000 | · | 97,900,000 | 97,600,000 | 97,100,000 | · | 95,800,000 | |
| Shares (Diluted) | 104,200,000 | 103,400,000 | · | 102,500,000 | 101,000,000 | 102,500,000 | · | 104,300,000 | 103,900,000 | 103,600,000 | · | 101,100,000 | 100,200,000 | 97,100,000 | · | 99,000,000 | |
| EBITDA | $152M | $193M | · | $239M | $146M | $24M | · | $184M | $145M | $99M | · | $141M | $74M | $-114M | · | $88M |
Bilanço
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $332M | $266M | $713M | $340M | $264M | $194M | $233M | $349M | $140M | $396M | · | $294M | $160M | $104M | · | $212M | |
| Receivables | $887M | $768M | $687M | $728M | $596M | $516M | $479M | $481M | $468M | $451M | · | $418M | $388M | $392M | · | $301M | |
| Inventory | $104M | $64M | $69M | $69M | $57M | $59M | $57M | $46M | $42M | $37M | · | $29M | $32M | $33M | · | $37M | |
| Prepaid Expense | $217M | $225M | $171M | $178M | · | · | $48M | · | · | · | · | · | · | · | · | · | |
| Other Current Assets | $39M | $62M | $116M | $68M | $121M | $119M | $64M | $122M | $120M | $100M | · | $108M | $101M | $113M | · | $68M | |
| Current Assets | $1.64B | $2.44B | $2.52B | $2.16B | $1.75B | $1.64B | $1.72B | $1.88B | $1.67B | $1.80B | · | $1.65B | $1.50B | $1.43B | · | $1.21B | |
| PP&E (Net) | $90M | $91M | $90M | $97M | $92M | $87M | $83M | $80M | $80M | $75M | · | $69M | $66M | $63M | · | $61M | |
| PP&E (Gross) | · | · | $208M | · | · | · | $189M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $118M | · | · | · | $106M | · | · | · | · | · | · | · | · | · | |
| Goodwill | $501M | · | · | · | · | · | · | $6M | $6M | $6M | · | $6M | $6M | $6M | $5M | · | |
| Intangibles | $2.23B | · | · | $36M | $37M | $36M | · | $34M | $34M | $34M | · | $35M | $37M | $37M | · | · | |
| Other Non-current Assets | $59M | $74M | $60M | $20M | $22M | $15M | $52M | $62M | $58M | $51M | · | $43M | $36M | $25M | · | $10M | |
| Total Assets | $5.36B | $4.91B | $4.63B | $4.27B | $3.89B | $3.69B | $3.72B | $3.54B | $3.31B | $3.47B | · | $2.85B | $2.61B | $2.36B | · | $2.14B | |
| Accounts Payable | $808M | $773M | $674M | $584M | $490M | $475M | $462M | $393M | $358M | $417M | · | $503M | $392M | $356M | · | $298M | |
| Current Liabilities | $874M | $832M | $743M | $638M | $546M | $523M | $508M | $430M | $398M | $713M | · | $692M | $582M | $374M | · | $485M | |
| Capital Leases | $402M | $406M | $415M | $428M | $439M | $448M | $455M | $251M | $256M | $253M | · | $86M | $89M | $90M | · | $97M | |
| Deferred Tax | $92M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Other Non-current Liabilities | $298M | $261M | $220M | $196M | $210M | $182M | $166M | $135M | $141M | $120M | · | $69M | $88M | $41M | · | $17M | |
| Total Liabilities | $1.67B | $1.50B | $1.38B | $1.26B | $1.20B | $1.15B | $1.13B | $816M | $796M | $1.09B | · | $846M | $760M | $675M | · | $599M | |
| Common Stock | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | · | $100.0K | $100.0K | $100.0K | · | $100.0K | |
| Retained Earnings | $724M | $590M | $448M | $294M | $84M | $-5M | $29M | $81M | $-49M | $-114M | · | $-305M | $-388M | $-483M | · | $-496M | |
| AOCI | $5M | $400.0K | $13M | $13M | $12M | $9M | $6M | $14M | $2M | $3M | · | $-2M | $-1M | $-3M | · | $-14M | |
| Stockholders' Equity | $3.69B | $3.41B | $3.25B | $3.00B | $2.69B | $2.54B | $2.59B | $2.72B | $2.51B | $2.39B | $2.23B | $2.00B | $1.85B | $1.68B | $1.71B | $1.54B | |
| Liabilities + Equity | $5.36B | $4.91B | $4.63B | $4.27B | $3.89B | $3.69B | $3.72B | $3.54B | $3.31B | $3.47B | · | $2.85B | $2.61B | $2.36B | · | $2.14B | |
| Shares Outstanding | 101,600,000 | 100,600,000 | 100,100,000 | 99,700,000 | 99,000,000 | 99,000,000 | 99,400,000 | 101,200,000 | 100,900,000 | 100,600,000 | · | 98,200,000 | 97,600,000 | 97,500,000 | · | 96,100,000 |
Nakit Akışı
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $65M | $57M | $59M | $54M | $53M | $53M | $66M | $42M | $43M | $44M | $38M | $48M | $68M | $40M | $44M | $43M | |
| Amort. of Intangibles | $16M | $100.0K | $1M | $1M | $1M | $1M | $900.0K | $900.0K | $900.0K | $900.0K | $800.0K | $900.0K | $900.0K | $900.0K | $500.0K | $0 | |
| Operating Cash Flow | $136M | $146M | $388M | $228M | $102M | $65M | $242M | $158M | $65M | $130M | $124M | $212M | $180M | $-125M | $143M | $99M | |
| CapEx | $8M | $9M | $-2M | $13M | $12M | $11M | $7M | $8M | $12M | $11M | $5M | $8M | $7M | $8M | $2M | $-2M | |
| Investing Cash Flow | $-135M | $-506M | $-53M | $-197M | $-29M | $14M | $-68M | $25M | $-28M | $-55M | $-202M | $-97M | $-126M | $-42M | $-116M | $-61M | |
| Stock Issued | $85M | $24M | $37M | $46M | $14M | $32M | $10M | $26M | $16M | $70M | $35M | $19M | $3M | $8M | $25M | $11M | |
| Stock Repurchased | $12M | $54M | $0 | $0 | $18M | $150M | $300M | $0 | $0 | $0 | · | · | · | · | · | · | |
| Net Stock Activity | · | $-30M | · | · | · | $-118M | · | · | · | $70M | · | · | · | $8M | · | · | |
| Financing Cash Flow | $63M | $-86M | $37M | $46M | $-3M | $-118M | $-290M | $26M | $-293M | $70M | $35M | $19M | $3M | $8M | $25M | $11M | |
| Net Change in Cash | $64M | $-446M | $373M | $76M | $70M | $-39M | $-116M | $209M | $-257M | $145M | $-43M | $134M | $57M | $-159M | $51M | $49M | |
| Free Cash Flow | · | $137M | · | · | · | $54M | · | · | · | $119M | · | · | · | $-134M | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $118M | · | · | · | $-135M | · | · |
Kârlılık
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 15.8% | 23.7% | · | 30.1% | 21.2% | 4.1% | · | 29.5% | 24.6% | 19.3% | · | 28.3% | 16.3% | -27.2% | · | 22.6% | |
| Net Margin | 15.1% | 24.3% | · | 26.4% | 15.6% | 1.4% | · | 20.9% | 11.0% | 8.4% | · | 16.7% | 21.1% | -18.2% | · | 17.7% | |
| Pretax Margin | 16.9% | 30.3% | · | 36.7% | 23.2% | 2.6% | · | 30.6% | 16.7% | 6.7% | · | 23.2% | 26.9% | -24.6% | · | 25.2% | |
| EBITDA Margin | 15.8% | 23.7% | · | 30.1% | 21.2% | 4.1% | · | 29.5% | 24.6% | 19.3% | · | 28.3% | 16.3% | -27.2% | · | 22.6% | |
| ROA | 3.1% | 4.6% | · | 5.4% | 3.0% | 0.22% | · | 4.1% | 2.2% | 1.5% | · | 3.3% | 4.1% | -3.4% | · | 3.3% | |
| ROE | 4.5% | 6.7% | · | 7.3% | 4.1% | 0.32% | · | 5.5% | 3.0% | 2.1% | · | 4.7% | 5.8% | -5.0% | · | 4.7% | |
| ROIC | 3.6% | 4.5% | · | 5.7% | 3.6% | 0.50% | · | 4.6% | 3.8% | 5.2% | · | 5.1% | 3.1% | -5.0% | · | 4.0% |
Likidite ve Solventlik
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.9 | 2.9 | · | 3.4 | 3.2 | 3.1 | · | 4.4 | 4.2 | 2.5 | · | 2.4 | 2.6 | 3.8 | · | 2.5 | |
| Quick Ratio | 1.4 | 1.2 | · | 1.7 | 1.6 | 1.4 | · | 1.9 | 1.5 | 1.2 | · | 1.0 | 0.9 | 1.3 | · | 1.1 | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | 90.3 | · | 128.4 | 56.6 | -103.8 | · | 73.2 |
Verimlilik
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | |
| Inventory Turnover | · | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.3 | 0.4 | 0.3 | · | 0.2 | |
| Receivables Turnover | 1.3 | 1.3 | · | 1.3 | 1.3 | 1.2 | · | 1.4 | 1.4 | 1.2 | · | 1.4 | 1.4 | 1.3 | · | 1.7 |
Hisse Başına
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $36.35 | $33.87 | · | $30.13 | $27.22 | $25.61 | · | $26.87 | $24.87 | $23.72 | · | $20.39 | $18.99 | $17.28 | · | $16.07 | |
| Revenue / Share | $9.20 | $7.88 | · | $7.76 | $6.81 | $5.59 | · | $5.96 | $5.68 | $4.97 | · | $4.93 | $4.52 | $4.33 | · | $3.92 | |
| Cash Flow / Share | · | $1.41 | · | · | · | $0.63 | · | · | · | $1.26 | · | · | · | $-1.29 | · | · | |
| Cash / Share | $3.27 | $2.65 | · | $3.41 | $2.67 | $1.96 | · | $3.45 | $1.38 | $3.94 | · | $2.99 | $1.64 | $1.06 | · | $2.21 | |
| EPS (TTM) | $6.83 | $6.50 | · | $4.18 | $3.38 | $2.95 | · | $3.78 | $3.36 | $3.68 | · | $1.89 | $1.76 | $0.63 | · | $0.58 |
Değerleme (TTM)
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $3.37B | $3.10B | · | $2.68B | $2.51B | $2.41B | · | $2.24B | $2.12B | $1.98B | · | $1.78B | $1.67B | $1.60B | · | $1.39B | |
| Net Income TTM | $706M | $669M | · | $428M | $348M | $306M | · | $386M | $339M | $370M | · | $191M | $176M | $64M | · | $58M | |
| Market Cap | $17.12B | $13.25B | · | $14.00B | $12.44B | $10.95B | · | $11.66B | $13.89B | $13.87B | · | $11.05B | $9.20B | $9.87B | · | $10.21B | |
| P/E | 24.7 | 20.3 | · | 33.6 | 37.2 | 37.5 | · | 30.5 | 41.0 | 37.5 | · | 59.5 | 53.6 | 160.7 | · | 183.1 | |
| P/S | 5.1 | 4.3 | · | 5.2 | 5.0 | 4.5 | · | 5.2 | 6.6 | 7.0 | · | 6.2 | 5.5 | 6.2 | · | 7.3 | |
| P/B | 4.6 | 3.9 | · | 4.7 | 4.6 | 4.3 | · | 4.3 | 5.5 | 5.8 | · | 5.5 | 5.0 | 5.9 | · | 6.6 | |
| P / Tangible Book | 17.7 | 3.9 | · | 4.7 | 4.7 | 4.4 | · | 4.4 | 5.6 | 5.9 | · | 5.6 | 5.1 | 6.0 | · | 6.6 | |
| P / Cash Flow | · | 90.9 | · | · | · | 169.0 | · | · | · | 106.5 | · | · | · | -78.8 | · | · | |
| Earnings Yield | 4.0% | 4.9% | · | 3.0% | 2.7% | 2.7% | · | 3.3% | 2.4% | 2.7% | · | 1.7% | 1.9% | 0.62% | · | 0.55% |
En son dönem solda · null değerler · olarak gösterilir
Finansal Tablolar Gelir tablosu, bilanço, nakit akışı — yıllık, son 5 yıl
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Gelir | $2.86B | $2.36B | $1.89B | $1.49B | $1.13B |
| Faaliyet Kâr Marjı % | 21.6% | 24.2% | 13.3% | 16.7% | 9.0% |
| Net Gelir | $479M | $341M | $250M | $154M | $90M |
| Seyreltilmiş Hisse Başı Kâr | $4.67 | $3.29 | $2.47 | $1.56 | $0.92 |
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Cari Oran | 3.4 | 3.4 | 2.5 | 2.7 | 4.0 |
| Cari Oran | 1.9 | 1.4 | 1.1 | 1.1 | 3.6 |
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Serbest Nakit Akışı | $749M | $557M | $362M | $323M | $233M |
Kurumsal Sahipler (13F) 825 dosya · $18.1B toplam · Tarih itibarıyla 30 Eylül 2026
Çeyreklik SEC Form 13F'lerinde bu hisse senedini tuttuklarını bildiren kurumlar. Yalnızca uzun pozisyonlar; tek bir başvuru sahibi, ayrı opsiyon bacakları için iki kez görünebilir. Büyük dengeleyici alım/satım bacakları genellikle piyasa yapımını veya korunmuş envanteri yansıtır, yönlü bir inancı değil.
Sahipler
825
Tutulan Değer
$18.1B
Yeni pozisyonlar
148
Çıkan pozisyonlar
62
Kurumsal faaliyet — Q2 2026 ve önceki çeyrek
| Yeni pozisyonlar | Çıkan pozisyonlar | Artırıldı | Azaldı | Net hisse senedi değişimi |
|---|---|---|---|---|
| 148 (+50 önceki Ç'ye göre) | 62 (-36 önceki Ç'ye göre) | 317 (+16 önceki Ç'ye göre) | 226 (+12 önceki Ç'ye göre) | +587K |
Q1 2026 ile karşılaştırıldı. SEC Form 13F başvuruları, çeyrek sonundan itibaren 45 gün içinde ve geç başvuranlar için kısa bir ek süre içinde tamamlanmalıdır — bu pencere içindeki çeyrekler, en son tam olarak raporlanan çifte tercih edilerek atlanır.
| Kurum | Değer | Hisse senetleri | % izlenen 13F'nin | Tür |
|---|---|---|---|---|
| BlackRock, Inc. | $2.310.885.707 | 13.711.607 | 12,75% | Hisse senetleri |
| VANGUARD GROUP INC | $1.375.793.692 | 9.700.301 | 7,59% | Hisse senetleri |
| JPMORGAN CHASE & CO | $1.088.569.109 | 6.398.674 | 6,01% | Hisse senetleri |
| Dodge & Cox | $941.218.594 | 5.584.707 | 5,19% | Hisse senetleri |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $838.307.078 | 4.974.083 | 4,63% | Hisse senetleri |
| VANGUARD CAPITAL MANAGEMENT LLC | $766.048.708 | 4.545.339 | 4,23% | Hisse senetleri |
| STATE STREET CORP | $739.126.759 | 4.385.598 | 4,08% | Hisse senetleri |
| AQR CAPITAL MANAGEMENT LLC | $643.472.716 | 3.818.037 | 3,55% | Hisse senetleri |
| RENAISSANCE TECHNOLOGIES LLC | $393.680.402 | 2.335.897 | 2,17% | Hisse senetleri |
| GEODE CAPITAL MANAGEMENT, LLC | $359.607.676 | 2.138.777 | 1,98% | Hisse senetleri |
| TWO SIGMA INVESTMENTS, LP | $349.922.479 | 2.076.260 | 1,93% | Hisse senetleri |
| Vestal Point Capital, LP | $316.845.800 | 1.880.000 | 1,75% | Hisse senetleri |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | $251.858.951 | 1.494.259 | 1,39% | Hisse senetleri |
| MORGAN STANLEY | $222.231.858 | 1.318.607 | 1,23% | Hisse senetleri |
| RTW INVESTMENTS, LP | $213.689.740 | 1.267.925 | 1,18% | Hisse senetleri |
| NORTHERN TRUST CORP | $212.306.405 | 1.259.717 | 1,17% | Hisse senetleri |
| Invesco Ltd. | $181.565.621 | 1.077.317 | 1,00% | Hisse senetleri |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $164.200.136 | 974.279 | 0,91% | Hisse senetleri |
| NORGES BANK | $164.132.866 | 973.880 | 0,91% | Hisse senetleri |
| FIRST TRUST ADVISORS LP | $155.578.851 | 923.125 | 0,86% | Hisse senetleri |
| DIMENSIONAL FUND ADVISORS LP | $123.525.529 | 732.877 | 0,68% | Hisse senetleri |
| JACOBS LEVY EQUITY MANAGEMENT, INC | $122.375.286 | 726.112 | 0,68% | Hisse senetleri |
| TWO SIGMA ADVISERS, LP | $119.504.823 | 842.592 | 0,66% | Hisse senetleri |
| Bank of New York Mellon Corp | $117.826.993 | 699.125 | 0,65% | Hisse senetleri |
| Swedbank AB | $109.730.107 | 651.082 | 0,61% | Hisse senetleri |
| VANGUARD FIDUCIARY TRUST CO | $109.170.737 | 647.763 | 0,60% | Hisse senetleri |
| IEQ CAPITAL, LLC | $107.913.614 | 640.304 | 0,60% | Hisse senetleri |
| GOLDMAN SACHS GROUP INC | $106.495.877 | 631.892 | 0,59% | Hisse senetleri |
| BANK OF AMERICA CORP /DE/ | $104.382.489 | 619.352 | 0,58% | Hisse senetleri |
| VICTORY CAPITAL MANAGEMENT INC | $104.238.729 | 618.499 | 0,58% | Hisse senetleri |
| Man Group plc | $101.292.738 | 601.019 | 0,56% | Hisse senetleri |
| ROYAL BANK OF CANADA | $98.337.000 | 583.476 | 0,54% | Hisse senetleri |
| RAYMOND JAMES FINANCIAL INC | $97.778.953 | 580.170 | 0,54% | Hisse senetleri |
| FRANKLIN RESOURCES INC | $93.211.316 | 553.068 | 0,51% | Hisse senetleri |
| UBS Group AG | $92.009.492 | 545.937 | 0,51% | Hisse senetleri |
| Caisse de depot et placement du Quebec | $91.002.327 | 539.961 | 0,50% | Hisse senetleri |
| ARMISTICE CAPITAL, LLC | $90.307.457 | 535.838 | 0,50% | Hisse senetleri |
| AMERIPRISE FINANCIAL INC | $84.660.571 | 502.267 | 0,47% | Hisse senetleri |
| PRIMECAP MANAGEMENT CO/CA/ | $82.807.988 | 491.340 | 0,46% | Hisse senetleri |
| Hood River Capital Management LLC | $79.082.184 | 469.233 | 0,44% | Hisse senetleri |
| Nuveen, LLC | $77.408.341 | 459.301 | 0,43% | Hisse senetleri |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $75.318.261 | 571.719 | 0,42% | Hisse senetleri |
| Pictet Asset Management Holding SA | $72.751.030 | 430.635 | 0,40% | Hisse senetleri |
| Rockefeller Capital Management L.P. | $62.955.982 | 373.548 | 0,35% | Hisse senetleri |
| Fiera Capital Corp | $62.895.914 | 373.192 | 0,35% | Hisse senetleri |
| Gotham Asset Management, LLC | $62.622.213 | 371.568 | 0,35% | Hisse senetleri |
| JANUS HENDERSON GROUP PLC | $61.515.240 | 466.977 | 0,34% | Hisse senetleri |
| ALLIANCEBERNSTEIN L.P. | $60.767.710 | 461.270 | 0,34% | Hisse senetleri |
| Vinva Investment Management Ltd | $58.838.530 | 346.109 | 0,32% | Hisse senetleri |
| AustralianSuper Pty Ltd | $58.817.535 | 348.993 | 0,32% | Hisse senetleri |
Aktivistler ve %5+ sahipler 1 pozisyon
SEC Çizelge 13D dosyalayan yatırımcılar — ihraççı üzerinde nüfuz etme niyetiyle %5'in üzerinde faydalı sahiplik (aktivist hisseler, yönetim kurulu kampanyaları, M&A). Her satır, o başvuru sahibinin pozisyonunun bilinen en son durumunu gösterir.
| Başvuru sahibi | Dosyalandı | Hisse | Durum | Amaç | Başvuru |
|---|---|---|---|---|---|
| Neurocrine Biosciences, Inc. ×3 başvurular | 24 Şubat 2023 | · | İlk başvuru | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Şirket yöneticileri 41 içeriden öğrenenler · 22 yöneticiler · 15 yönetim kurulu üyeleri
| İçeriden Öğrenen | Rol | Son işlem | Sahip olunan hisse senetleri | Alımlar 12ay | Satışlar 12ay | Net 12ay |
|---|---|---|---|---|---|---|
| Kyle Gano | Chief Executive Officer | 11 Eylül 2026 F | 154.728 | 0 | 3 | $-4.872.890 |
| Matt Abernethy | Chief Financial Officer | 14 Eylül 2026 S | 42.808 | 0 | 1 | $-363.289 |
| Timothy Coughlin | Chief Financial Officer | 06 Şubat 2017 S | 137.961 | 0 | 0 | $0 |
| David-Alexandre C Gros | President & COO | 06 Şubat 2017 A | · | 0 | 0 | $0 |
| David W. Boyer | Chief Corp. Affairs Officer | 14 Eylül 2026 S | 8.722 | 0 | 2 | $-739.070 |
| Ingrid Delaet | Chief Regulatory Officer | 11 Eylül 2026 F | 18.289 | 0 | 5 | $-3.747.962 |
| Jude Onyia | Chief Scientific Officer | 11 Eylül 2026 F | 22.647 | 0 | 2 | $-3.473.580 |
| Sanjay Chandru Keswani | Chief Medical Officer | 11 Eylül 2026 F | 3.281 | 0 | 0 | $0 |
| Julie Cooke | Chief Human Resources Officer | 11 Eylül 2026 F | 24.025 | 0 | 5 | $-5.770.377 |
| Eric Benevich | Chief Commercial Officer | 11 Eylül 2026 F | 67.297 | 0 | 2 | $-1.238.918 |
| Darin Lippoldt | Chief Legal Officer | 11 Eylül 2026 F | 56.793 | 0 | 5 | $-4.196.071 |
| Eiry Roberts | Chief Medical Officer | 13 Şubat 2025 M | 35.640 | 0 | 0 | $0 |
| Malcolm Lloyd-Smith | Chief Integration Officer | 08 Şubat 2023 S | 42.337 | 0 | 0 | $0 |
| Dimitri E. Grigoriadis | Chief Research Officer | 31 Ocak 2022 A | 82.273 | 0 | 0 | $0 |
| Haig P. Bozigian | Chief Development Officer | 08 Şubat 2021 A | 157.651 | 0 | 0 | $0 |
| Christopher Flint Obrien | Former Chief Medical Officer | 05 Şubat 2018 A | 55.946 | 0 | 0 | $0 |
| VALEUR JENSEN MARGARET E | EVP and General Counsel | 31 Ağustos 2011 A | 118.256 | 0 | 0 | $0 |
| Richard J Ranieri | Sr. VP, Human Resources | 27 Şubat 2008 A | 9.667 | 0 | 0 | $0 |
| Wendall Wierenga | EVP, Research & Development | 19 Ocak 2006 A | 5.023 | 0 | 0 | $0 |
| Henry Pan | Executive VP and CMO | 03 Haziran 2005 A | 11.216 | 0 | 0 | $0 |
| Robert J Little | SVP, Commercial Operations | 18 Şubat 2005 A | · | 0 | 0 | $0 |
| SAUNDERS JOHN | Vice President Research (Chem) | 18 Aralık 2003 S | 7.966 | 0 | 0 | $0 |
| Kevin Charles Gorman | Yönetim kurulu üyesi | 11 Eylül 2026 F | 517.797 | 0 | 1 | $-37.824.431 |
| SHERWIN STEPHEN A | Yönetim kurulu üyesi | 02 Eylül 2026 G | 14.860 | 0 | 5 | $-4.132.990 |
| Leslie V Norwalk | Yönetim kurulu üyesi | 29 Temmuz 2026 M | 2.430 | 0 | 5 | $-1.973.882 |
| Johanna Mercier | Yönetim kurulu üyesi | 27 Mayıs 2026 A | 6.853 | 0 | 0 | $0 |
| William H Rastetter | Yönetim kurulu üyesi | 27 Mayıs 2026 A | 43.678 | 0 | 1 | $-2.732.760 |
| Christine A Poon | Yönetim kurulu üyesi | 27 Mayıs 2026 A | 4.753 | 0 | 0 | $0 |
| POPS RICHARD F | Yönetim kurulu üyesi | 27 Mayıs 2026 A | 37.798 | 0 | 1 | $-2.364.750 |
| LYONS GARY A | Yönetim kurulu üyesi | 27 Mayıs 2026 A | 122.141 | 0 | 1 | $-2.289.150 |
| MORROW GEORGE J | Yönetim kurulu üyesi | 27 Mayıs 2026 A | 10.386 | 0 | 1 | $-2.150.550 |
| Alfred Sandrock | Yönetim kurulu üyesi | 22 Mayıs 2019 A | · | 0 | 0 | $0 |
| Corinne H Nevinny | Yönetim kurulu üyesi | 24 Mayıs 2018 A | 43.283 | 0 | 0 | $0 |
| Thomas W Mitchell | Yönetim kurulu üyesi | 28 Mayıs 2015 A | 1.000 | 0 | 0 | $0 |
| VALE WYLIE W | Yönetim kurulu üyesi | 25 Mayıs 2011 A | 231.372 | 0 | 0 | $0 |
| Adrian Adams | Yönetim kurulu üyesi | 30 Haziran 2006 A | · | 0 | 0 | $0 |
| Shalini Sharp | · | 27 Mayıs 2026 A | 4.088 | 0 | 0 | $0 |
| MOLLICA JOSEPH A | · | 22 Mayıs 2017 A | 56.042 | 0 | 0 | $0 |
| HAWRAN PAUL W | · | 18 Eylül 2006 J | 132.000 | 0 | 0 | $0 |
| Lawrence Steinman | · | 02 Mart 2005 S | 15.500 | 0 | 0 | $0 |
| CONLON PAUL J | · | 16 Aralık 2003 S | 57.335 | 0 | 0 | $0 |
SEC Form 3/4/5 başvurularından yöneticiler; net = yalnızca açık piyasa Alış/Satış
ETF sahipliği 104 ETF'ler tarafından tutuluyor
Ağırlık yalnızca doğrudan öz sermaye varlıklarını (N-PORT) yansıtır; kaldıraçlı veya türev tabanlı fonlar gösterilmeyen ek swap pozisyonlarına sahip olabilir.
| Fon | Ağırlık | Birimler | Tarih itibarıyla | Kaynak |
|---|---|---|---|---|
| IBRN · iShares Trust | 3,75% | 1.793 SH | 11 Eylül 2026 | Günlük |
| PBE · Invesco Exchange-Traded Fund Trust | 2,60% | 76.511 SH | 02 Ekim 2026 | Günlük |
| MCOW · Pacer Funds Trust | 2,57% | 164 NS | 31 Temmuz 2026 | N-PORT |
| BUL · Pacer Funds Trust | 2,15% | 16.896 NS | 31 Temmuz 2026 | N-PORT |
| CVSM · Elevation Series Trust | 2,04% | 11.525 NS | 31 Temmuz 2026 | N-PORT |
| JMID · Janus Detroit Street Trust | 1,93% | 2.742 NS | 31 Temmuz 2026 | N-PORT |
| POWA · Invesco Exchange-Traded Self-Indexe… | 1,92% | 22.570 SH | 02 Ekim 2026 | Günlük |
| FGSI · First Trust Exchange-Traded Fund IV | 1,90% | 236 NS | 31 Temmuz 2026 | N-PORT |
| ABOT · Abacus FCF ETF Trust | 1,90% | 460 NS | 31 Temmuz 2026 | N-PORT |
| XMHQ · Invesco Exchange-Traded Fund Trust | 1,74% | 667.222 SH | 02 Ekim 2026 | Günlük |
| FXH · First Trust Exchange-Traded AlphaDE… | 1,67% | 105.135 NS | 31 Temmuz 2026 | N-PORT |
| GRPM · Invesco Exchange-Traded Fund Trust | 1,61% | 56.862 SH | 02 Ekim 2026 | Günlük |
| BBP · ETFis Series Trust I | 1,44% | 8.494 NS | 31 Temmuz 2026 | N-PORT |
| CSMD · Professionally Managed Portfolios | 1,18% | 32.094 NS | 31 Temmuz 2026 | N-PORT |
| IBB · iShares Trust | 1,14% | 755.021 SH | 11 Eylül 2026 | Günlük |
| AGRW · ALLSPRING EXCHANGE-TRADED FUNDS TRU… | 1,11% | 7.516 NS | 31 Temmuz 2026 | N-PORT |
| JSMD · Janus Detroit Street Trust | 1,05% | 66.455 NS | 31 Temmuz 2026 | N-PORT |
| RFG · Invesco Exchange-Traded Fund Trust | 1,04% | 24.859 SH | 02 Ekim 2026 | Günlük |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,96% | 7.190 SH | 02 Ekim 2026 | Günlük |
| IVOG · VANGUARD ADMIRAL FUNDS | 0,89% | 99.214 SH | 19 Ağustos 2026 | Günlük |
| COWG · Pacer Funds Trust | 0,78% | 103.520 NS | 31 Temmuz 2026 | N-PORT |
| JDOC · J.P. Morgan Exchange-Traded Fund Tr… | 0,73% | 399 NS | 31 Temmuz 2026 | N-PORT |
| LSEQ · Harbor ETF Trust | 0,72% | 661 NS | 31 Temmuz 2026 | N-PORT |
| QQQJ · Invesco Exchange-Traded Fund Trust … | 0,72% | 59.939 SH | 02 Ekim 2026 | Günlük |
| LABU · Direxion Shares ETF Trust | 0,71% | 20.978 NS | 31 Temmuz 2026 | N-PORT |
| IQSM · New York Life Investments ETF Trust | 0,63% | 12.528 NS | 31 Temmuz 2026 | N-PORT |
| FNY · First Trust Exchange-Traded AlphaDE… | 0,63% | 21.784 NS | 31 Temmuz 2026 | N-PORT |
| QLV · FlexShares Trust | 0,56% | 5.460 NS | 31 Temmuz 2026 | N-PORT |
| ISCG · iShares Trust | 0,52% | 31.868 SH | 11 Eylül 2026 | Günlük |
| PTMC · Pacer Funds Trust | 0,47% | 11.072 NS | 31 Temmuz 2026 | N-PORT |
| USMV · iShares Trust | 0,46% | 697.795 SH | 11 Eylül 2026 | Günlük |
| VBK · VANGUARD INDEX FUNDS | 0,46% | 1.331.820 SH | 19 Ağustos 2026 | Günlük |
| IVOO · VANGUARD ADMIRAL FUNDS | 0,46% | 162.408 SH | 19 Ağustos 2026 | Günlük |
| QVMM · Invesco Exchange-Traded Fund Trust … | 0,45% | 13.252 SH | 02 Ekim 2026 | Günlük |
| SMDX · Tidal Trust III | 0,43% | 3.374 NS | 31 Temmuz 2026 | N-PORT |
| BKMC · BNY Mellon ETF Trust | 0,42% | 16.429 NS | 31 Temmuz 2026 | N-PORT |
| IWP · iShares Trust | 0,39% | 480.949 SH | 11 Eylül 2026 | Günlük |
| SDG · iShares Trust | 0,38% | 4.071 SH | 11 Eylül 2026 | Günlük |
| BBMC · J.P. Morgan Exchange-Traded Fund Tr… | 0,36% | 44.021 NS | 31 Temmuz 2026 | N-PORT |
| MIDU · Direxion Shares ETF Trust | 0,36% | 1.476 NS | 31 Temmuz 2026 | N-PORT |
| FSMD · FIDELITY COVINGTON TRUST | 0,31% | 46.187 NS | 31 Temmuz 2026 | N-PORT |
| FNX · First Trust Exchange-Traded AlphaDE… | 0,30% | 24.447 NS | 31 Temmuz 2026 | N-PORT |
| JPME · J.P. Morgan Exchange-Traded Fund Tr… | 0,29% | 8.053 NS | 31 Temmuz 2026 | N-PORT |
| COWZ · Pacer Funds Trust | 0,25% | 283.150 NS | 31 Temmuz 2026 | N-PORT |
| IYH · iShares Trust | 0,25% | 57.843 SH | 11 Eylül 2026 | Günlük |
| VHT · VANGUARD WORLD FUND | 0,24% | 286.599 SH | 19 Ağustos 2026 | Günlük |
| FHLC · FIDELITY COVINGTON TRUST | 0,23% | 45.259 NS | 31 Temmuz 2026 | N-PORT |
| SMMD · iShares Trust | 0,21% | 52.744 SH | 11 Eylül 2026 | Günlük |
| EUSA · iShares, Inc. | 0,20% | 25.089 SH | 11 Eylül 2026 | Günlük |
| VB · VANGUARD INDEX FUNDS | 0,20% | 2.306.077 SH | 19 Ağustos 2026 | Günlük |
| PWS · Pacer Funds Trust | 0,20% | 287 NS | 31 Temmuz 2026 | N-PORT |
| SIZE · iShares Trust | 0,20% | 5.417 SH | 11 Eylül 2026 | Günlük |
| VXF · VANGUARD INDEX FUNDS | 0,19% | 1.153.763 SH | 19 Ağustos 2026 | Günlük |
| FAD · First Trust Exchange-Traded AlphaDE… | 0,19% | 6.541 NS | 31 Temmuz 2026 | N-PORT |
| ACWV · iShares, Inc. | 0,18% | 37.854 SH | 11 Eylül 2026 | Günlük |
| RWK · Invesco Exchange-Traded Fund Trust … | 0,13% | 11.381 SH | 02 Ekim 2026 | Günlük |
| IWR · iShares Trust | 0,11% | 405.396 SH | 11 Eylül 2026 | Günlük |
| FHEQ · Fidelity Greenwood Street Trust | 0,11% | 6.157 NS | 31 Temmuz 2026 | N-PORT |
| ESUM · Strategy Shares | 0,10% | 1.133 NS | 31 Temmuz 2026 | N-PORT |
| HEQQ · J.P. Morgan Exchange-Traded Fund Tr… | 0,10% | 177 NS | 31 Temmuz 2026 | N-PORT |
| LRND · New York Life Investments ETF Trust | 0,10% | 2.270 NS | 31 Temmuz 2026 | N-PORT |
| HELO · J.P. Morgan Exchange-Traded Fund Tr… | 0,09% | 23.838 NS | 31 Temmuz 2026 | N-PORT |
| EQAL · Invesco Exchange-Traded Fund Trust … | 0,09% | 4.828 SH | 02 Ekim 2026 | Günlük |
| DFUV · Dimensional ETF Trust | 0,08% | 70.759 NS | 31 Temmuz 2026 | N-PORT |
| OMFL · Invesco Exchange-Traded Self-Indexe… | 0,07% | 23.598 SH | 02 Ekim 2026 | Günlük |
| DYNF · BlackRock ETF Trust | 0,07% | 177.312 SH | 11 Eylül 2026 | Günlük |
| USXF · iShares Trust | 0,06% | 5.665 SH | 11 Eylül 2026 | Günlük |
| ESMV · iShares Trust | 0,05% | 26 SH | 11 Eylül 2026 | Günlük |
| GARP · iShares Trust | 0,05% | 9.869 SH | 11 Eylül 2026 | Günlük |
| DFAC · Dimensional ETF Trust | 0,05% | 141.631 NS | 31 Temmuz 2026 | N-PORT |
| DXUV · Dimensional ETF Trust | 0,05% | 1.484 NS | 31 Temmuz 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0,04% | 8.569 NS | 31 Temmuz 2026 | N-PORT |
| IUSG · iShares Trust | 0,04% | 89.338 SH | 11 Eylül 2026 | Günlük |
| IWF · iShares Trust | 0,04% | 320.069 SH | 11 Eylül 2026 | Günlük |
| VONG · VANGUARD SCOTTSDALE FUNDS | 0,04% | 134.662 SH | 19 Ağustos 2026 | Günlük |
| ESGV · VANGUARD WORLD FUND | 0,03% | 22.375 SH | 19 Ağustos 2026 | Günlük |
| TILT · FlexShares Trust | 0,03% | 3.888 NS | 31 Temmuz 2026 | N-PORT |
| DFAU · Dimensional ETF Trust | 0,03% | 20.775 NS | 31 Temmuz 2026 | N-PORT |
| RECS · Columbia ETF Trust I | 0,02% | 8.549 NS | 31 Temmuz 2026 | N-PORT |
| DFUS · Dimensional ETF Trust | 0,02% | 28.885 NS | 31 Temmuz 2026 | N-PORT |
| IYY · iShares Trust | 0,02% | 4.355 SH | 11 Eylül 2026 | Günlük |
| IWB · iShares Trust | 0,02% | 68.459 SH | 11 Eylül 2026 | Günlük |
| ITOT · iShares Trust | 0,02% | 131.068 SH | 11 Eylül 2026 | Günlük |
| IWS · iShares Trust | 0,02% | 20.508 SH | 11 Eylül 2026 | Günlük |
| IWV · iShares Trust | 0,02% | 27.012 SH | 11 Eylül 2026 | Günlük |
| PBUS · Invesco Exchange-Traded Fund Trust … | 0,02% | 16.531 SH | 02 Ekim 2026 | Günlük |
| VTI · VANGUARD INDEX FUNDS | 0,02% | 3.193.839 SH | 19 Ağustos 2026 | Günlük |
| VONE · VANGUARD SCOTTSDALE FUNDS | 0,02% | 16.227 SH | 19 Ağustos 2026 | Günlük |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,02% | 8.342 SH | 19 Ağustos 2026 | Günlük |
| PRF · Invesco Exchange-Traded Fund Trust | 0,02% | 11.591 SH | 02 Ekim 2026 | Günlük |
| TOK · iShares Trust | 0,02% | 249 SH | 11 Eylül 2026 | Günlük |
| URTH · iShares, Inc. | 0,02% | 8.440 SH | 11 Eylül 2026 | Günlük |
| ACWI · iShares Trust | 0,01% | 30.548 SH | 11 Eylül 2026 | Günlük |
| DFLV · Dimensional ETF Trust | 0,01% | 4.926 NS | 31 Temmuz 2026 | N-PORT |
| DFVX · Dimensional ETF Trust | 0,01% | 323 NS | 31 Temmuz 2026 | N-PORT |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0,01% | 85.082 SH | 19 Ağustos 2026 | Günlük |
| VONV · VANGUARD SCOTTSDALE FUNDS | 0,01% | 8.319 SH | 19 Ağustos 2026 | Günlük |
| FYEE · Fidelity Greenwood Street Trust | 0,01% | 110 NS | 31 Temmuz 2026 | N-PORT |
| REVS · Columbia ETF Trust I | 0,01% | 124 NS | 31 Temmuz 2026 | N-PORT |
| IWD · iShares Trust | 0,01% | 30.627 SH | 11 Eylül 2026 | Günlük |
| IJH · iShares Trust | · | 3.528.125 SH | 11 Eylül 2026 | Günlük |
| IJK · iShares Trust | · | 582.451 SH | 11 Eylül 2026 | Günlük |
| XJH · iShares Trust | · | 13.736 SH | 08 Eylül 2026 | Günlük |
| ISCB · iShares Trust | · | 4.526 SH | 11 Eylül 2026 | Günlük |
NBIX Analist Uzlaşması Boğa ve ayı analist görüşleri, 12 aylık fiyat hedefi, yukarı yönlü potansiyel
derecelendirme · 36 analist
AL
Medyan hedef
$214.00
+48,4%
14 38,9%
Güçlü Al
17 47,2%
Al
5 13,9%
Tut
0 0,0%
Sat
0 0,0%
Güçlü Sat
12 Aylık Fiyat Hedefi
29 analist · 2026-10-03Ortalama hedef $207.81 +44,1%
← Tüm hedeflerin altında
Mevcut fiyat $144.21
Düşük$164.00
Ortalama$207.81
Yüksek$253.00
Akran karşılaştırması (GICS alt sektörü) Anahtar metrikler sektördeki benzerlerine karşı
Mali yıl bazında, fiyatlar her şirketin son mali yıl kapanışına göredir.
| Hisse Sembolü | Piyasa Değeri | P/E | Gelir YoY | Net Kar Marjı | ROE | Brüt Kar Marjı |
|---|---|---|---|---|---|---|
| NBIX | $14.20B | 30.4 | 21.4% | 16.7% | 16.1% | · |
| ALNY | $52.64B | 170.7 | 65.2% | 8.5% | 60.4% | · |
| UTHR | $21.27B | 17.5 | 10.6% | 41.9% | 18.7% | 87.9% |
| INCY | $19.60B | 15.4 | 21.2% | 25.0% | 27.6% | · |
| INSM | $37.29B | -27.1 | 66.7% | -210.5% | -128.4% | · |
| EXEL | $11.44B | 15.7 | 7.0% | 33.7% | 37.3% | · |
| SMMT | $13.56B | -12.1 | · | · | -235.1% | · |
| TWST | $1.71B | -21.6 | 20.3% | -20.6% | -17.0% | · |
| BBIO | $14.90B | -20.2 | 126.3% | -146.0% | 41.2% | · |
| HALO | $7.93B | 26.3 | 37.5% | 22.7% | 166.1% | · |
| MDGL | $13.30B | -45.3 | 432.1% | -30.1% | -44.4% | · |
Son Haberler Bu şirketten bahseden son manşetler
Aralık 2027 Seçenekleri Şimdi Neurocrine Biosciences (NBIX) İçin Mevcut
Nasdaq · 5 ay, 4 hafta önce
Bugün Borsa, 6 Nisan: Soleno Therapeutics, 2,9 Milyar Dolarlık Nakit Satın Alma Anlaşmasının Ardından Yükseldi
Nasdaq · 5 ay, 4 hafta önce
Neurocrine, Soleno'yu 2,9 Milyar Dolara Nakit Anlaşmayla Satın Alacak; Soleno Hisseleri İşlem Öncesi Yükseliyor
Nasdaq · 5 ay, 4 hafta önce
İşlem Sinyalleri Giriş fiyatı ve risk/ödül oranı ile son alım/satım sinyalleri
BLUECHIP_DIP
Zarar durduruldu
risk 1
ödül 1,67
giriş
$156.04
R:R 1,67
BLUECHIP_DIP
Zarar durduruldu
risk 1
ödül 2,78
giriş
$161.50
R:R 2,78
BLUECHIP_DIP
Süresi Doldu
risk 1
ödül 5,00
giriş
$129.88
R:R 5,00
BLUECHIP_DIP
Zarar durduruldu
risk 1
ödül 4,80
giriş
$132.67
R:R 4,80
BLUECHIP_DIP
Zarar durduruldu
risk 1
ödül 5,00
giriş
$132.79
R:R 5,00
Şu anda açık sinyal yok — hiçbir kart dolu değil ve bu dürüstçe.
Metriklerim Kişisel izleme listeniz — Tam Temeller'den seçilen satırlar
Sizin için önemli olan metrikleri seçin — Yukarıdaki Tam Temeller bölümündeki herhangi bir satırın yanındaki + işaretine tıklayın.
Seçiminiz kaydedildi ve tüm hisse senetlerinde sizinle birlikte gelir.
Kaynak: SEC 10-Q dosyalandı Tem 31, 2026